AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11170981 — intervention group
Group type: EXPERIMENTAL
Intervention: CP Vac-Env-Pro
Number of subjects: 59
Study 11170981 — intervention group
Group type: COMPARATOR
Intervention: Control (CP rabies or gp120 vaccine only)
Number of subjects: 59
Study 11170981 — intervention group
Group type: EXPERIMENTAL
Intervention: rgp120
Number of subjects: 59
Study 9756781 — intervention group
Group type: EXPERIMENTAL
Intervention: Pleconaril oral solution (200 mg) coadministered with a standard English breakfast
Number of subjects: 12
Study 9756781 — intervention group
Group type: COMPARATOR
Intervention: Pleconaril oral solution (200 mg) in fasting state
Number of subjects: 12
Study 9756781 — intervention group
Group type: EXPERIMENTAL
Intervention: Pleconaril oral solution (200 mg)
Number of subjects: 12
Study 7876406 — intervention group
Group type: EXPERIMENTAL
Intervention: CI-977 (5 micrograms)
Number of subjects: 16
Study 7876406 — intervention group
Group type: EXPERIMENTAL
Intervention: CI-977 (15 micrograms)
Number of subjects: 16
Study 7876406 — intervention group
Group type: EXPERIMENTAL
Intervention: CI-977 (25 micrograms)
Number of subjects: 16
Study 7876406 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 3278595 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat probe thermocoagulation
Number of subjects: 78
Study 3278595 — intervention group
Group type: COMPARATOR
Intervention: Pure alcohol injection
Number of subjects: 78
Study 31049139 — intervention group
Group type: EXPERIMENTAL
Intervention: Cordyceps militaris (COG, 100 mg daily)
Number of subjects: 0
Study 28434116 — intervention group
Group type: EXPERIMENTAL
Intervention: IDO activity
Number of subjects: 149
Study 28434116 — intervention group
Group type: EXPERIMENTAL
Intervention: TPH activity
Number of subjects: 149
Study 25350981 — intervention group
Group type: EXPERIMENTAL
Intervention: Droxidopa (100-600 mg, 3× daily)
Number of subjects: 101
Study 25350981 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 101
Study 25350981 — intervention group
Group type: EXPERIMENTAL
Intervention: Droxidopa
Number of subjects: 101
Study 25350981 — intervention group
Group type: COMPARATOR
Intervention: Droxidopa and Placebo
Number of subjects: 101
Study 23404689 — intervention group
Group type: EXPERIMENTAL
Intervention: Cell salvage of cardiotomy suction blood
Number of subjects: 25
Study 23404689 — intervention group
Group type: COMPARATOR
Intervention: No cell salvage
Number of subjects: 25
Study 21602542 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluctuations in twice‐daily peak expiratory flow (PEF) over 6 months
Number of subjects: 291
Study 21602542 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean percentage predicted PEF (%predPEF)
Number of subjects: 291
Study 18581891 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous injection of salmon calcitonin (50 U) three times a week for 18 months
Number of subjects: 108
Study 18581891 — intervention group
Group type: COMPARATOR
Intervention: Oral administration of calcium carbonate 1500 mg tid and rocaltrol 0.25 microg qn for 18 months (Control)
Number of subjects: 108
Study 16344320 — intervention group
Group type: EXPERIMENTAL
Intervention: FDR gemcitabine 1,000 mg/m2 at 10 mg/m2/min with cisplatin 20 mg/m2 on days 1 and 8 of a 21-day cycle
Number of subjects: 51
Study 16344320 — intervention group
Group type: EXPERIMENTAL
Intervention: FDR gemcitabine with cisplatin
Number of subjects: 51
Study 12975186 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold gel (Ice Power)
Number of subjects: 74
Study 12975186 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 74
Study 10800798 — intervention group
Group type: EXPERIMENTAL
Intervention: heparin-coated circuit with aprotinin (HCO-A)
Number of subjects: 200
Study 10800798 — intervention group
Group type: EXPERIMENTAL
Intervention: heparin-coated circuit without aprotinin (HCO)
Number of subjects: 200
Study 10800798 — intervention group
Group type: EXPERIMENTAL
Intervention: uncoated circuit with aprotinin (C-A)
Number of subjects: 200
Study 10800798 — intervention group
Group type: COMPARATOR
Intervention: uncoated circuit without aprotinin (C)
Number of subjects: 200
Study 8738684 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol and alfentanil anesthesia (PA)
Number of subjects: 39
Study 8738684 — intervention group
Group type: COMPARATOR
Intervention: Thiopental and nitrous oxide anesthesia (TN)
Number of subjects: 39
Study 8738684 — intervention group
Group type: COMPARATOR
Intervention: Comparison of sick-leave between PA and TN groups
Number of subjects: 39
Study 8738684 — intervention group
Group type: COMPARATOR
Intervention: Economic impact of sick-leave
Number of subjects: 39
Study 1640004 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline 100 mg administered twice on day 8
Number of subjects: 20
Study 1640004 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered twice on day 8
Number of subjects: 20
Study 6090529 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine
Number of subjects: 50
Study 6090529 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine
Number of subjects: 50
Study 31227317 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous anesthesia with propofol
Number of subjects: 183
Study 31227317 — intervention group
Group type: COMPARATOR
Intervention: Desflurane anesthesia
Number of subjects: 183
Study 29699403 — intervention group
Group type: EXPERIMENTAL
Intervention: Gluten consumption between 11 and 36 months
Number of subjects: 225
Study 29699403 — intervention group
Group type: EXPERIMENTAL
Intervention: HLA genotype
Number of subjects: 225
Study 29699403 — intervention group
Group type: EXPERIMENTAL
Intervention: Female gender
Number of subjects: 225
Study 29699403 — intervention group
Group type: COMPARATOR
Intervention: Gluten consumption among three centers
Number of subjects: 225
Study 29699403 — intervention group
Group type: COMPARATOR
Intervention: Celiac vs non-celiac children
Number of subjects: 225
Study 27270645 — intervention group
Group type: EXPERIMENTAL
Intervention: Embedded cognitive rehabilitation intervention (n = 10)
Number of subjects: 18
Study 27270645 — intervention group
Group type: COMPARATOR
Intervention: Supportive client-centered therapy (control, n = 8)
Number of subjects: 18
Study 24962744 — intervention group
Group type: EXPERIMENTAL
Intervention: BMT+TAG
Number of subjects: 61
Study 24962744 — intervention group
Group type: COMPARATOR
Intervention: BMT
Number of subjects: 61
Study 22389945 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Orientation to daily Occupational Performance (CO‐OP)
Number of subjects: 8
Study 22389945 — intervention group
Group type: COMPARATOR
Intervention: Standard Occupational Therapy (SOT)
Number of subjects: 8
Study 20407057 — intervention group
Group type: EXPERIMENTAL
Intervention: Early tracheotomy (n = 209; 145 received tracheotomy)
Number of subjects: 600
Study 20407057 — intervention group
Group type: COMPARATOR
Intervention: Late tracheotomy (n = 210; 119 received tracheotomy)
Number of subjects: 600
Study 20407057 — intervention group
Group type: EXPERIMENTAL
Intervention: Early tracheotomy
Number of subjects: 600
Study 18672641 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinaril (20 mg quinapril hydrochloride)
Number of subjects: 24
Study 16091254 — intervention group
Group type: EXPERIMENTAL
Intervention: Immune-based therapies as an adjunct to antiretroviral treatment
Number of subjects: 0
Study 16091254 — intervention group
Group type: EXPERIMENTAL
Intervention: Immune-based therapies
Number of subjects: 0
Study 16091254 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunomodulating therapies
Number of subjects: 0
Study 16091254 — intervention group
Group type: EXPERIMENTAL
Intervention: Methods targeting the latent memory T-cell reservoir of virus
Number of subjects: 0
Study 12093332 — intervention group
Group type: EXPERIMENTAL
Intervention: Bovine pericardium (BP)
Number of subjects: 92
Study 12093332 — intervention group
Group type: COMPARATOR
Intervention: Dacron
Number of subjects: 92
Study 10575530 — intervention group
Group type: EXPERIMENTAL
Intervention: Reteplase (administered in bolus injections)
Number of subjects: 0
Study 10575530 — intervention group
Group type: EXPERIMENTAL
Intervention: Bolus TNK-t-PA
Number of subjects: 0
Study 7677218 — intervention group
Group type: EXPERIMENTAL
Intervention: Paromomycin ointment applied twice a day from day 1 through day 14
Number of subjects: 115
Study 7677218 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 115
Study 7677218 — intervention group
Group type: EXPERIMENTAL
Intervention: Paromomycin ointment
Number of subjects: 115
Study 7677218 — intervention group
Group type: COMPARATOR
Intervention: Paromomycin ointment and Placebo
Number of subjects: 115
Study 2148282 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoximone
Number of subjects: 20
Study 2148282 — intervention group
Group type: EXPERIMENTAL
Intervention: Dobutamine
Number of subjects: 20
Study 382379 — intervention group
Group type: COMPARATOR
Intervention: Antibiotics + Placebo
Number of subjects: 378
Study 382379 — intervention group
Group type: COMPARATOR
Intervention: Antibiotics + Pseudoephedrine
Number of subjects: 378
Study 382379 — intervention group
Group type: COMPARATOR
Intervention: Antibiotics + Triprolidine
Number of subjects: 378
Study 382379 — intervention group
Group type: COMPARATOR
Intervention: Antibiotics + Combination of agents
Number of subjects: 378
Study 31821157 — intervention group
Group type: EXPERIMENTAL
Intervention: β-hydroxybutyrate infusion
Number of subjects: 18
Study 31821157 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline) infusion
Number of subjects: 18
Study 30420448 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipilimumab 10 mg/kg + High-Dose Interferon-α2b (HDI)
Number of subjects: 81
Study 30420448 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipilimumab 10 mg/kg
Number of subjects: 81
Study 30420448 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipilimumab 3 mg/kg + High-Dose Interferon-α2b (HDI)
Number of subjects: 81
Study 30420448 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipilimumab 3 mg/kg
Number of subjects: 81
Study 30420448 — intervention group
Group type: COMPARATOR
Intervention: Ipilimumab alone
Number of subjects: 81
Study 28985039 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-fat diet high in monounsaturated fatty acids (MUFA)
Number of subjects: 3
Study 28985039 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat, high-fiber diet (Nordic Nutrition Recommendations [NNR])
Number of subjects: 3
Study 28985039 — intervention group
Group type: EXPERIMENTAL
Intervention: Average Danish Diet (ADD)
Number of subjects: 3
Study 28985039 — intervention group
Group type: COMPARATOR
Intervention: Comparison of NNR to ADD
Number of subjects: 3
Study 28985039 — intervention group
Group type: COMPARATOR
Intervention: Comparison of NNR to MUFA
Number of subjects: 3
Study 26232942 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary infusion of cardiosphere-derived cells (CDCs)
Number of subjects: 14
Study 26232942 — intervention group
Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 14
Study 23478743 — intervention group
Group type: EXPERIMENTAL
Intervention: Aliskiren (150 mg daily, increased to 300 mg as tolerated)
Number of subjects: 1615
Study 23478743 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1615
Study 23478743 — intervention group
Group type: EXPERIMENTAL
Intervention: Aliskiren
Number of subjects: 1615
Study 21099417 — intervention group
Group type: EXPERIMENTAL
Intervention: T-Clair SPHP700-3
Number of subjects: 60
Study 21099417 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 18355658 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline LOOH levels in the highest quartile
Number of subjects: 634
Study 18355658 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine treatment
Number of subjects: 634
Study 16736344 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin (1 x 10(6) KIU loading dose before surgery and 5 x 10(5) KIU/h during surgery, gross dose: 2.5 x 10(6) KIU, n=36)
Number of subjects: 76
Study 16736344 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin
Number of subjects: 76
Study 16736344 — intervention group
Group type: COMPARATOR
Intervention: Saline solution (control, n=40)
Number of subjects: 76
Study 14508028 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular sleep after vaccination
Number of subjects: 19
Study 14508028 — intervention group
Group type: COMPARATOR
Intervention: Staying awake after vaccination
Number of subjects: 19
Study 11057006 — intervention group
Group type: EXPERIMENTAL
Intervention: Translated two‐object contours
Number of subjects: 0
Study 11057006 — intervention group
Group type: EXPERIMENTAL
Intervention: Symmetrical contours at different axis orientations
Number of subjects: 0
Study 1360793 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside (n = 11)
Number of subjects: 21
Study 1360793 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoldopam mesylate (n = 10)
Number of subjects: 21
Study 1360793 — intervention group
Group type: COMPARATOR
Intervention: Both treatments (Sodium nitroprusside and Fenoldopam)
Number of subjects: 21
Study 2418716 — intervention group
Group type: EXPERIMENTAL
Intervention: Atracurium 1.2 mg . kg‐1
Number of subjects: 30
Study 2418716 — intervention group
Group type: EXPERIMENTAL
Intervention: Atracurium 0.2 mg . kg‐1
Number of subjects: 30
Study 2418716 — intervention group
Group type: EXPERIMENTAL
Intervention: Atracurium 0.6 mg . kg‐1
Number of subjects: 30
Study 31366601 — intervention group
Group type: EXPERIMENTAL
Intervention: mogamulizumab‐kpkc
Number of subjects: 372
Study 31366601 — intervention group
Group type: COMPARATOR
Intervention: vorinostat
Number of subjects: 372
Study 29716555 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic radical hysterectomy (RRH)
Number of subjects: 60
Study 29716555 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic radical hysterectomy (LRH)
Number of subjects: 60
Study 27138794 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene (120 mg per day orally)
Number of subjects: 20
Study 27138794 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 24161158 — intervention group
Group type: EXPERIMENTAL
Intervention: MMF/prednisone
Number of subjects: 84
Study 24161158 — intervention group
Group type: COMPARATOR
Intervention: CYC/prednisone
Number of subjects: 84
Study 22041458 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion
Number of subjects: 1439
Study 22041458 — intervention group
Group type: COMPARATOR
Intervention: Not available
Number of subjects: 1439
Study 19743503 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous atacicept (single dose: 0.3, 1, 3, or 9 mg/kg; four weekly doses: 1 or 3 mg/kg)
Number of subjects: 96
Study 19743503 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous atacicept (single dose: 3, 9, or 18 mg/kg; multiple dose: 2 x 9 mg/kg)
Number of subjects: 96
Study 19743503 — intervention group
Group type: COMPARATOR
Intervention: Placebo (3:1 ratio for Study 1; 5:1 ratio for Study 2)
Number of subjects: 96
Study 19031818 — intervention group
Group type: EXPERIMENTAL
Intervention: Palatoplasty at age ≤ 3.0 years (Group A)
Number of subjects: 103
Study 19031818 — intervention group
Group type: EXPERIMENTAL
Intervention: Palatoplasty at age > 6.0 years (Group C)
Number of subjects: 103
Study 16261757 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Politzer device used in home setting over a 7-week period
Number of subjects: 94
Study 16261757 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 94
Study 11849464 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive blood pressure control (10 mm Hg below baseline DBP)
Number of subjects: 480
Study 11849464 — intervention group
Group type: COMPARATOR
Intervention: Moderate blood pressure control (80 to 89 mm Hg)
Number of subjects: 480
Study 10190639 — intervention group
Group type: EXPERIMENTAL
Intervention: Community intervention including community education, merchant education, and voluntary policy change.
Number of subjects: 100
Study 10190639 — intervention group
Group type: COMPARATOR
Intervention: Comparison communities (no intervention).
Number of subjects: 100
Study 10190639 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention communities for younger students (7th graders).
Number of subjects: 100
Study 10190639 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention communities for older students (9th and 11th graders).
Number of subjects: 100
Study 10190639 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention communities for females.
Number of subjects: 100
Study 8916626 — intervention group
Group type: COMPARATOR
Intervention: therapy
Number of subjects: 0
Study 8916626 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 0
Study 2071252 — intervention group
Group type: EXPERIMENTAL
Intervention: Nisoldipine 10 mg twice daily
Number of subjects: 12
Study 2071252 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 6337605 — intervention group
Group type: EXPERIMENTAL
Intervention: Dazoxiben (thromboxane synthetase inhibitor)
Number of subjects: 0
Study 6337605 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30632915 — intervention group
Group type: EXPERIMENTAL
Intervention: In-depth interviews, photovoice, and participant observation
Number of subjects: 15
Study 30632915 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional and economic support from families
Number of subjects: 15
Study 27881556 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoxia (10% O2)
Number of subjects: 10
Study 27881556 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise in hypoxia (10% O2)
Number of subjects: 10
Study 27881556 — intervention group
Group type: COMPARATOR
Intervention: Normoxia (21% O2)
Number of subjects: 10
Study 27881556 — intervention group
Group type: COMPARATOR
Intervention: Exercise in normoxia (21% O2)
Number of subjects: 10
Study 26596405 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based tailored asthma intervention
Number of subjects: 499
Study 26596405 — intervention group
Group type: COMPARATOR
Intervention: Emergency department recruitment strategy
Number of subjects: 499
Study 26596405 — intervention group
Group type: COMPARATOR
Intervention: Mail or telephone recruitment strategy
Number of subjects: 499
Study 26596405 — intervention group
Group type: COMPARATOR
Intervention: Emergency department awareness activities
Number of subjects: 499
Study 24589198 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific problem-solving training
Number of subjects: 0
Study 24589198 — intervention group
Group type: EXPERIMENTAL
Intervention: Basic cognition training
Number of subjects: 0
Study 22183156 — intervention group
Group type: EXPERIMENTAL
Intervention: Transversus abdominis plane block with 20 ml of levobupivacaine 2.5 mg/ml
Number of subjects: 40
Study 22183156 — intervention group
Group type: COMPARATOR
Intervention: Control group (no block)
Number of subjects: 40
Study 22183156 — intervention group
Group type: EXPERIMENTAL
Intervention: Transversus abdominis plane block
Number of subjects: 40
Study 22183156 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study 20801975 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (shared decision making tool - ARRIBA‐Herz)
Number of subjects: 1132
Study 20801975 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1132
Study 17940609 — intervention group
Group type: EXPERIMENTAL
Intervention: AMA1-C1 vaccine (5, 20, and 80 microg doses)
Number of subjects: 54
Study 17940609 — intervention group
Group type: EXPERIMENTAL
Intervention: AMA1-C1 vaccine (80 microg dose)
Number of subjects: 54
Study 17940609 — intervention group
Group type: EXPERIMENTAL
Intervention: AMA1-C1 vaccine (third dose at one year)
Number of subjects: 54
Study 17940609 — intervention group
Group type: EXPERIMENTAL
Intervention: AMA1-C1 vaccine
Number of subjects: 54
Study 17940609 — intervention group
Group type: COMPARATOR
Intervention: Control vaccine (Hepatitis B vaccine - Recombivax)
Number of subjects: 54
Study 15494430 — intervention group
Group type: EXPERIMENTAL
Intervention: R‐CVP (CVP plus rituximab)
Number of subjects: 321
Study 15494430 — intervention group
Group type: COMPARATOR
Intervention: CVP (control)
Number of subjects: 321
Study 12076551 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (increased fruit and vegetable consumption)
Number of subjects: 690
Study 10211630 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast cancer patients
Number of subjects: 35
Study 10211630 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast cancer patients with stage III
Number of subjects: 35
Study 10211630 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 35)
Number of subjects: 35
Study 7840291 — intervention group
Group type: COMPARATOR
Intervention: Athletes
Number of subjects: 25
Study 7840291 — intervention group
Group type: COMPARATOR
Intervention: Hypertensives
Number of subjects: 25
Study 1849532 — intervention group
Group type: EXPERIMENTAL
Intervention: Informed group (received letter about elevated blood pressure)
Number of subjects: 36
Study 1849532 — intervention group
Group type: EXPERIMENTAL
Intervention: Informed group
Number of subjects: 36
Study 1849532 — intervention group
Group type: COMPARATOR
Intervention: Control group (received neutral letter)
Number of subjects: 36
Study 7314869 — intervention group
Group type: EXPERIMENTAL
Intervention: Sympathectomy
Number of subjects: 183
Study 7314869 — intervention group
Group type: COMPARATOR
Intervention: No operation (Control)
Number of subjects: 183
Study 31911146 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose inactivated influenza vaccine (15 μg of each of the three seasonal influenza strains)
Number of subjects: 800
Study 31911146 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-dose inactivated influenza vaccine (15 μg of each of the three seasonal influenza strains)
Number of subjects: 800
Study 31911146 — intervention group
Group type: EXPERIMENTAL
Intervention: Two single doses of inactivated influenza vaccine (15 μg of each of the three seasonal influenza strains, 1 month apart)
Number of subjects: 800
Study 31911146 — intervention group
Group type: COMPARATOR
Intervention: Double-dose inactivated influenza vaccine
Number of subjects: 800
Study 31615643 — intervention group
Group type: EXPERIMENTAL
Intervention: Forward walking at preferred walking speed (PWS) for 3 minutes (pre) followed by 5 minutes walking at 80%, 100%, and 120% of PWS (forward walking)
Number of subjects: 22
Study 31615643 — intervention group
Group type: EXPERIMENTAL
Intervention: Backward walking at 80%, 100%, and 120% of PWS
Number of subjects: 22
Study 31615643 — intervention group
Group type: EXPERIMENTAL
Intervention: Backward walking
Number of subjects: 22